KFAS
KRYS icon

Keating Financial Advisory Services’s Krystal Biotech KRYS Stock Holding History

Keating Financial Advisory Services’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.5K Buy
39
+11
+39% +$3.29K ﹤0.01% 1108
2026
Q1 		$7.23K Buy
28
+23
+460% +$6.12K ﹤0.01% 1258
2025
Q4 		$1.23K Buy
+5
New +$1.05K ﹤0.01% 1734

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Keating Financial Advisory Services's KRYS Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Krystal Biotech (KRYS) stake by 39% in Q2 2026, buying an estimated $3.29K and bringing the position to 39 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1108.

Keating Financial Advisory Services first reported a position in KRYS in Q4 2025 and has held it in 3 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Keating Financial Advisory Services held 39 shares of Krystal Biotech worth $14.5K as of Q2 2026.
  • Keating Financial Advisory Services bought 11 Krystal Biotech shares in Q2 2026, an estimated $3.29K.
  • Krystal Biotech made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1108 holding.
  • Keating Financial Advisory Services first reported a position in Krystal Biotech in Q4 2025 and has held it in 3 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.